Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against bluebird bio, Inc.
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) – Wolf Haldenstein Adler Freeman & Herz LLP announces that Bluebird Bio, Inc. (“Bluebird” or the “Company “) (NASDAQ: BLUE) and some of its officers on behalf of shareholders who purchased or otherwise acquired Bluebird securities between May 11, 2020 and November 4, 2020, both dates inclusive (the” School Lesson “).
All investors who bought shares of Bluebird Bio, Inc.. and any losses incurred are requested to contact the company immediately firstname.lastname@example.org or (800) 575-0735 or (212) 545-4774. You can get additional information about the promotion or Join the case on our website, www.whafh.com.
If you have suffered losses in the stocks of Bluebird Bio, Inc.., You may, no later than April 13, 2021, Ask the court to appoint you as the lead plaintiff in the proposed class. Please contact Wolf Haldenstein to find out more about your rights as an investor in shares of Bluebird Bio, Inc.
CLICK HERE TO JOIN CASE
The complaint filed alleges that throughout the class period, defendants made materially false and / or misleading statements and failed to advise investors that:
- Data in support of Bluebird’s BLA filing for LentiGlobin for SCD were insufficient to demonstrate drug comparability;
- Defendants have downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the company’s BLA filing schedule for LentiGlobin for SCD, particularly with respect to manufacturing.
- As a result of the foregoing, it was foreseeable that the company would not file the BLA for LentiGlobin for SCD in the second half of 2021. and
- As a result, the company’s public statements have been materially false and misleading at all relevant times.
Company shares fell as much as 35% for the day on February 16, 2020 after the company announced the suspension of its Phase 1/2 and Phase 3 trials of its sickle cell therapy candidate.
The company has suspended the studies because of a reported suspected unexpected serious side effect (SUSAR) in acute myeloid leukemia (AML). Bluebird put the study on hold after receiving reports last week that a patient who was treated in a study more than five years ago was diagnosed with AML.
Wolf Haldenstein has extensive experience prosecuting class and derivative disputes in state and federal courts and appeals courts across the country. The firm has lawyers in various fields of activity; and offices in New York, Chicago and San Diego. This law firm’s reputation and expertise in shareholder and other class disputes has been recognized repeatedly by the courts who have appointed them to key positions in complex securities multiple district and consolidated litigation.
If you would like to discuss this campaign or if you have any questions about your rights and interests in this case, please contact Wolf Haldenstein immediately by telephone at (800) 575-0735, by email at email@example.com or visit our website on www.whafh.com.
Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, director of case and financial analysis
Email: firstname.lastname@example.org, email@example.com, or firstname.lastname@example.org
Tel .: (800) 575-0735 or (212) 545-4774
This press release may be viewed as a solicitor’s advertisement in some jurisdictions under applicable laws and ethical rules.